4th Actavis Ordinary Meeting at the AHA in Chicago

16.02.2011 13:31

Clinical PETN studies in focus

The Ordinary Meeting, which was organized by Actavis Germany for the fourth time in a row, took place in Chicago at the beginning of November. 21 German cardiology professors met on the sidelines of the annual congress of the American Heart Association to discuss the status of the two current studies CAESAR and CLEOPATRA, which are intended to expand the clinical data for PETN (Pentalong®).
The CAESAR study (Clinical efficacy study of Pentalong for pulmonary hypertension in heart failure) examines the effectiveness of PETN in pulmonary hypertension resulting from heart failure. The background is the lack of tolerance development for long-term nitrate. Under the direction of Professor Erland Erdmann, an earlier study at the Cologne Heart Center has already shown that PETN reduces pulmonary pressure in left heart failure persistently and without nitrate tolerance. The placebo-controlled study, scheduled to last twelve weeks, will be carried out in 15 university hospitals.
The double-blind, placebo-controlled CLEOPATRA study (Clinical efficacy of Pentalong® in stable angina pectoris after twelve weeks of routine administration) examines the clinical effectiveness of PETN under stress conditions. PETN is the most commonly prescribed long-term nitrate in the treatment of stable angina pectoris, not least because there is no drug tolerance. After 6 or 12 weeks of examination, the exercise capacity of the 778 patients with stable angina pectoris on the treadmill was measured and compared with the initial data.
According to Professor Karl Werdan from Halle ad Saale, CLEOPATRA takes into account the requirement of the revised national CHD care guidelines (NVL KHK) for randomized clinical trials for antianginal diseases.